A phase3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination for 12 weeks in Subjcts with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Clinical Trial Grant
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
July 1, 2015
End Date
June 30, 2017
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
July 1, 2015
End Date
June 30, 2017